Cerity Partners
RPRX icon

Cerity Partners’s Royalty Pharma RPRX Stock Holding History

Cerity Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
180,772
+19,342
+12% +$1.01M 0.01% 764
2026
Q1 		$7.74M Buy
161,430
+46,035
+40% +$2.02M 0.01% 822
2025
Q4 		$4.46M Buy
115,395
+34,420
+43% +$1.31M 0.01% 968
2025
Q3 		$2.86M Sell
80,975
-75,555
-48% -$2.74M ﹤0.01% 1121
2025
Q2 		$5.64M Buy
156,530
+2,684
+2% +$88.9K 0.01% 751
2025
Q1 		$4.79M Buy
153,846
+136,487
+786% +$4.33M 0.01% 749
2024
Q4 		$459K Sell
17,359
-15,537
-47% -$412K ﹤0.01% 1814
2024
Q3 		$931K Buy
32,896
+3,291
+11% +$91.2K ﹤0.01% 1430
2024
Q2 		$781K Sell
29,605
-6,822
-19% -$189K ﹤0.01% 1336
2024
Q1 		$1.11M Buy
36,427
+8,259
+29% +$243K ﹤0.01% 1230
2023
Q4 		$791K Buy
+28,168
New +$774K ﹤0.01% 1070
2023
Q3 		– Sell
-25,788
Closed -$793K – 1658
2023
Q2 		$793K Buy
25,788
+943
+4% +$31.9K ﹤0.01% 996
2023
Q1 		$893K Buy
24,845
+689
+3% +$25.5K ﹤0.01% 1027
2022
Q4 		$954K Buy
24,156
+177
+0.7% +$7.39K 0.01% 707
2022
Q3 		$963K Buy
23,979
+520
+2% +$22.2K 0.01% 530
2022
Q2 		$987K Buy
23,459
+2,567
+12% +$105K 0.01% 553
2022
Q1 		$813K Buy
+20,892
New +$820K 0.01% 483

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's RPRX Position: Q2 2026 in Review

Cerity Partners increased its Royalty Pharma (RPRX) stake by 12% in Q2 2026, buying an estimated $1.01M and bringing the position to 180,772 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #764.

Cerity Partners first reported a position in RPRX in Q1 2022 and has held it in 17 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cerity Partners held 180,772 shares of Royalty Pharma worth $10.1M as of Q2 2026.
  • Cerity Partners bought 19,342 Royalty Pharma shares in Q2 2026, an estimated $1.01M.
  • Royalty Pharma made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #764 holding.
  • Cerity Partners first reported a position in Royalty Pharma in Q1 2022 and has held it in 17 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.